Fri, Nov 19th, 2021 - 8:06am
November 01, 2021 - 7:21am | By Kyle Cornell
(Washington, DC) -- The FDA is delaying its study of Moderna's COVID-19 vaccine for teenagers.
That word comes from Moderna, which issued a news release on Sunday saying the FDA has indicated it'll take at least until January to complete its review of the Massachusetts-based biotech company's approval request for kids ages 12 to 17.
The FDA is looking at reports out of Japan and Nordic nations on the risk of myocarditis, or heart inflammation, that's occurred in rare cases in men ages 18 to 30. Sweden and Finland have recommended against giving Moderna's COVID-19 vax to men under thirty.
The company also said it's delaying asking the FDA to approve its vaccine for younger children too.
